Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128496 | 0.90 | BCHE (0.42) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL20128486 | 0.86 | TACR1 (0.42) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL20128481 | 0.83 | SPHK1 (0.41) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL20128479 | 0.83 | LMNA (0.51) | ALDH1A1SPHK2SPHK1GBA1 | |
| SCHEMBL19903874 | 0.83 | SPHK1 (0.41) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL9015295 | 0.83 | LMNA (0.51) | ALDH1A1SPHK2SPHK1GBA1 | |
| SCHEMBL24926340 | 0.81 | ACHE (0.45) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL17805425 | 0.81 | TACR1 (0.46) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL18801726 | 0.81 | TACR1 (0.46) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL12410196 | 0.81 | ACHE (0.45) | CYP2D6CYP1A2CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040760-B2 | Pyrrolidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127364-A1 | PYRROLIDINE COMPOUND | CAT, POLI, PPOX | CYP2D6 2099/4885CYP1A2 1239/4885CYP3A4 972/4885 |
| US-10040760-B2 | Pyrrolidine compound | CAT, POLI, PPOX | CYP2D6 2099/4885CYP1A2 1239/4885CYP3A4 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.